Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study
Stukas S, Goshua G, Kinkade A, Grey R, Mah G, Biggs CM, Jamal S, Thiara S, Lau TTY, Piszczek J, Partovi N, Sweet DD, Lee AYY, Wellington CL, Sekhon MS, Chen LYC. Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study. The Lancet Regional Health - Americas 2022, 11: 100228. PMID: 35345649, PMCID: PMC8941850, DOI: 10.1016/j.lana.2022.100228.Peer-Reviewed Original ResearchDoses of tocilizumabCohort studyClinical outcomesIll patientsIll COVID-19 patientsCOVID-19Interleukin-6 inhibitorsSevere COVID-19Weight-based dosingCOVID-19 patientsDrug shortagesNet monetary benefitMedian CRPControl cohortTocilizumabPatientsAssumed willingnessDexamethasoneComparable reductionMortalityPhysiological responsesSignificant differencesOnly groupDoseDoses